An Open-label, Non-randomized, Monocenter, Single-dose, Phase I Study to Evaluate Pharmacokinetics and Safety of POL7080 Administered as Single Intravenous Infusion to Subjects With Renal Impairment

Trial Profile

An Open-label, Non-randomized, Monocenter, Single-dose, Phase I Study to Evaluate Pharmacokinetics and Safety of POL7080 Administered as Single Intravenous Infusion to Subjects With Renal Impairment

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Murepavadin (Primary)
  • Indications Bacterial infections
  • Focus Pharmacokinetics
  • Sponsors Polyphor
  • Most Recent Events

    • 16 Jun 2016 Number of treatments arms changed from 5 to 6.
    • 12 Apr 2016 Results presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
    • 25 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top